Cargando…

Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset

BACKGROUND: The translocations of the anaplastic lymphoma kinase (ALK) gene with the echinoderm microtubule-associated protein-like 4 (EML4) gene on chromosome 2p have been identified in non-small-cell lung cancers (NSCLCs) as oncogenic driver mutations. It has been suggested that EML4-ALK fusion is...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yongjun, Ma, Jie, Lyu, Xiaodong, Liu, Hai, Wei, Bing, Zhao, Jiuzhou, Fu, Shuang, Ding, Lu, Zhang, Jihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240865/
https://www.ncbi.nlm.nih.gov/pubmed/25407901
http://dx.doi.org/10.1186/1471-2407-14-834
_version_ 1782345786322845696
author Guo, Yongjun
Ma, Jie
Lyu, Xiaodong
Liu, Hai
Wei, Bing
Zhao, Jiuzhou
Fu, Shuang
Ding, Lu
Zhang, Jihong
author_facet Guo, Yongjun
Ma, Jie
Lyu, Xiaodong
Liu, Hai
Wei, Bing
Zhao, Jiuzhou
Fu, Shuang
Ding, Lu
Zhang, Jihong
author_sort Guo, Yongjun
collection PubMed
description BACKGROUND: The translocations of the anaplastic lymphoma kinase (ALK) gene with the echinoderm microtubule-associated protein-like 4 (EML4) gene on chromosome 2p have been identified in non-small-cell lung cancers (NSCLCs) as oncogenic driver mutations. It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib. In contrast, ALK tyrosine kinase inhibitor (ALK TKI) crizotinib has shown superior effects in combating NSCLCs with EML4-ALK. Thus, characterization of EML4-ALK fusion genes and clinical features of resulting carcinomas would be a great benefit to disease diagnosis and designing customized treatment plans. Studies have suggested that EML4-ALK translocation occurs more frequently in never-smokers with NSCLC, especially in female patients. However, it is not clear whether this is the case in male patients, too. In this study, we have determined the frequency of EML4-ALK translocation in male never-smokers with NSCLC in a cohort of Chinese patients. The clinical features associated with EML4-ALK translocation were also investigated. METHODS: A cohort of 95 Chinese male never-smokers with NSCLC was enrolled in this study. EML4-ALK fusion genes were detected using one-step real time RT-PCR and DNA sequencing. We further determined the expression levels of ALK mRNA by RT-PCR and ALK protein by immunohistochemistry in these specimens. The clinical features of EML4-ALK–positive carcinomas were also determined. RESULTS: We have identified EML4-ALK fusion genes in 8 out of 95 carcinoma cases, accounting for 8.42% in Chinese male never-smokers with NSCLC. It is significantly higher than that in all Chinese male patients (3.44%) regardless smoking habit. It is also significantly higher than that in all Chinese smokers (8/356 or 2.25%) or in smokers worldwide (2.9%) by comparing to published data. Interestingly, EML4-ALK fusion genes are more frequently found in younger patients and associated with less-differentiated carcinomas. CONCLUSIONS: The frequency of EML4-ALK translocation is strongly associated with smoking habits in Chinese male patients with higher frequency in male never-smokers. EML4-ALK translocation is associated with early-onset and less-differentiated carcinomas.
format Online
Article
Text
id pubmed-4240865
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42408652014-11-23 Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset Guo, Yongjun Ma, Jie Lyu, Xiaodong Liu, Hai Wei, Bing Zhao, Jiuzhou Fu, Shuang Ding, Lu Zhang, Jihong BMC Cancer Research Article BACKGROUND: The translocations of the anaplastic lymphoma kinase (ALK) gene with the echinoderm microtubule-associated protein-like 4 (EML4) gene on chromosome 2p have been identified in non-small-cell lung cancers (NSCLCs) as oncogenic driver mutations. It has been suggested that EML4-ALK fusion is associated with the resistance in NSCLCs to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), such as gefitinib and erlotinib. In contrast, ALK tyrosine kinase inhibitor (ALK TKI) crizotinib has shown superior effects in combating NSCLCs with EML4-ALK. Thus, characterization of EML4-ALK fusion genes and clinical features of resulting carcinomas would be a great benefit to disease diagnosis and designing customized treatment plans. Studies have suggested that EML4-ALK translocation occurs more frequently in never-smokers with NSCLC, especially in female patients. However, it is not clear whether this is the case in male patients, too. In this study, we have determined the frequency of EML4-ALK translocation in male never-smokers with NSCLC in a cohort of Chinese patients. The clinical features associated with EML4-ALK translocation were also investigated. METHODS: A cohort of 95 Chinese male never-smokers with NSCLC was enrolled in this study. EML4-ALK fusion genes were detected using one-step real time RT-PCR and DNA sequencing. We further determined the expression levels of ALK mRNA by RT-PCR and ALK protein by immunohistochemistry in these specimens. The clinical features of EML4-ALK–positive carcinomas were also determined. RESULTS: We have identified EML4-ALK fusion genes in 8 out of 95 carcinoma cases, accounting for 8.42% in Chinese male never-smokers with NSCLC. It is significantly higher than that in all Chinese male patients (3.44%) regardless smoking habit. It is also significantly higher than that in all Chinese smokers (8/356 or 2.25%) or in smokers worldwide (2.9%) by comparing to published data. Interestingly, EML4-ALK fusion genes are more frequently found in younger patients and associated with less-differentiated carcinomas. CONCLUSIONS: The frequency of EML4-ALK translocation is strongly associated with smoking habits in Chinese male patients with higher frequency in male never-smokers. EML4-ALK translocation is associated with early-onset and less-differentiated carcinomas. BioMed Central 2014-11-18 /pmc/articles/PMC4240865/ /pubmed/25407901 http://dx.doi.org/10.1186/1471-2407-14-834 Text en © Guo et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Guo, Yongjun
Ma, Jie
Lyu, Xiaodong
Liu, Hai
Wei, Bing
Zhao, Jiuzhou
Fu, Shuang
Ding, Lu
Zhang, Jihong
Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset
title Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset
title_full Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset
title_fullStr Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset
title_full_unstemmed Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset
title_short Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset
title_sort non-small cell lung cancer with eml4-alk translocation in chinese male never-smokers is characterized with early-onset
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240865/
https://www.ncbi.nlm.nih.gov/pubmed/25407901
http://dx.doi.org/10.1186/1471-2407-14-834
work_keys_str_mv AT guoyongjun nonsmallcelllungcancerwitheml4alktranslocationinchinesemaleneversmokersischaracterizedwithearlyonset
AT majie nonsmallcelllungcancerwitheml4alktranslocationinchinesemaleneversmokersischaracterizedwithearlyonset
AT lyuxiaodong nonsmallcelllungcancerwitheml4alktranslocationinchinesemaleneversmokersischaracterizedwithearlyonset
AT liuhai nonsmallcelllungcancerwitheml4alktranslocationinchinesemaleneversmokersischaracterizedwithearlyonset
AT weibing nonsmallcelllungcancerwitheml4alktranslocationinchinesemaleneversmokersischaracterizedwithearlyonset
AT zhaojiuzhou nonsmallcelllungcancerwitheml4alktranslocationinchinesemaleneversmokersischaracterizedwithearlyonset
AT fushuang nonsmallcelllungcancerwitheml4alktranslocationinchinesemaleneversmokersischaracterizedwithearlyonset
AT dinglu nonsmallcelllungcancerwitheml4alktranslocationinchinesemaleneversmokersischaracterizedwithearlyonset
AT zhangjihong nonsmallcelllungcancerwitheml4alktranslocationinchinesemaleneversmokersischaracterizedwithearlyonset